half life of glp 1 agonists glp-1_analogs [TUSOM GLP-1 Agonists in Cardiovascular Diseases:
Description
Kim S, Jeong J, Jung H-S, Kim B, Kim YE, Lim DS, et al
P., Grieve D
Those with a BMI of 27 or higher who also have associated health conditions, such as type 2 diabetes, may also qualify
Krisanapan P, Sanpawithayakul K, Pattharanitima P, Thongprayoon C, Miao J, Mao MA, et al
Glucagon gene expression in the endocrine pancreas: the role of the transcription factor Pax6 in alpha-cell differentiation, glucagon biosynthesis and secretion
Habener, Mojsov, and Knudsen, who developed GLP-1 medicines that have revolutionized the treatment of obesity
